HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.

HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。

youdao

It is also approved for use in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.

该药与芳香化酶抑制剂联合使用治疗HER2和激素受体共同阳性乳腺癌的绝经后女性。

youdao

We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.

我们调查了HER 2异质性对112例her 2阳性转移性乳腺癌患者的曲妥珠单抗疗效和临床预后的影响。

youdao

Kadcyla, known as an "antibody-drug conjugate, " represents "a completely new way" to treat HER2 positive metastatic breast cancer, said Dr. Hal Barron, chief medical officer and head of global product development for Genentech.

CNN: New late-stage breast cancer treatment approved

The results were shown in the first randomized phase II study comparing trastuzumab-DM1 (T-DM1) to Herceptin (trastuzumab) plus chemotherapy (docetaxel), the current standard of care for first line HER2-positive metastatic breast cancer.

FORBES: Novartis Deal Bolsters Immunogen